Dornase Alfa Inhalation Solution [Pulmozyme]

DRUG2 trials

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild, University College, London

Conditions

Acute Respiratory Distress SyndromeCOVID-19COVID-19 (Coronavirus Disease 2019)Hypoxia

Phase 2

Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)

CompletedNCT04359654

University College, LondonCOVID-19 (Coronavirus Disease 2019), Hypoxia

Start: 2020-06-16End: 2021-11-05Updated: 2025-01-13

Phase 3

Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)

TerminatedNCT04355364

Fondation Ophtalmologique Adolphe de RothschildAcute Respiratory Distress Syndrome, COVID-19

Start: 2020-04-21End: 2021-12-20Updated: 2022-01-11

Related Papers

Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS.

2025-10-22

Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial.

2024-07-1613 citations

Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial

eLife2024-07-1510 citations

Impaired balance between neutrophil extracellular trap formation and degradation by DNases in COVID-19 disease.

2024-03-0712 citations

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19

Frontiers in Immunology2021-10-2072 citations

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial.

2020-06-1926 citations